The Acomplia Paradox: Primary Care Drug, Targeted Population

As Acomplia is launched across Europe, Sanofi Aventis' challenge is less about promoting the drug, than about limiting its use within the appropriate target group.

Melanie Senior

Sanofi-Aventis’ rimonabant (Acomplia) was never going to fit neatly into any of the industry’s pre-defined categories. Approved in Europe in...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from In Vivo Archive

More from In Vivo